The performance of the novel chitin metal silicate (CMS) co-precipitates as a\r\nsingle multifunctional excipient in tablet formulation using direct compression and wet\r\ngranulation methods is evaluated. The neutral, acidic, and basic drugs Spironolactone\r\n(SPL), ibuprofen (IBU) and metronidazole (MET), respectively, were used as model drugs.\r\nCommercial Aldactone�®, Fleximex�® and Dumazole�® tablets containing SPL, IBU and\r\nMET, respectively, and tablets made using Avicel�® 200, were used in the study for\r\ncomparison purposes. Tablets of acceptable crushing strength (>40 N) were obtained using\r\nCMS. The friability values for all tablets were well below the maximum 1% USP tolerance\r\nlimit. CMS produced superdisintegrating tablets (disintegration time < 1 min) with the\r\nthree model drugs. Regarding the dissolution rate, the sequence was as follow:\r\nCMS > Fleximex�® > Avicel�® 200, CMS > Avicel�® 200 > Dumazole�® and Aldactone�® >\r\nAvicel�® 200 > CMS for IBU, MET and SPL, respectively. Compressional properties of\r\nformulations were analyzed using density measurements and the compression Kawakita\r\nequation as assessment parameters. On the basis of DSC results, CMS co precipitates were\r\nfound to be compatible with the tested drugs. Conclusively, the CMS co-precipitates have the potential to be used as filler, binder, and superdisintegrant, all-in-one, in the design of\r\ntablets by the direct compression as well as wet granulation methods.
Loading....